| Document |
Document Title |
|
WO/2018/128587A1 |
Disclosed is an isolated variant of SMCHD1 peptide, or fragment thereof, comprising one or more mutation(s) that increases SMCHD1 activity in a cell compared to a cell with a wild- etype SMCHD1 peptide. Also disclosed are isolated nuclei...
|
|
WO/2018/129395A1 |
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.
|
|
WO/2018/129315A1 |
The invention relates to methods and compositions comprising a TRP channel or ASIC channel activator for preventing or treating a disease, disorder, or condition described herein.
|
|
WO/2018/129434A1 |
The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrom...
|
|
WO/2018/124292A1 |
Provided is a method for inducing skeletal muscle cells, the method comprising a step for introducing an MyoD family gene or an expression product thereof, and an Myc family gene or an expression product thereof into mammalian somatic ce...
|
|
WO/2018/120920A1 |
Disclosed is a cisatracurium besilate lyophilized powder-injection preparation for intravenous administration, which is made of the following components in parts by weight: 1-5 parts of cisatracurium besilate, 10-40 parts of dimyristoylp...
|
|
WO/2018/124011A1 |
The purpose of the present invention is to provide a motor control function improving agent that improves motor control functions which have deteriorated due to aging or fatigue, and a method for evaluating or selecting the motor control...
|
|
WO/2018/124258A1 |
The present invention can provide: a prophylactic or ameliorating/therapeutic agent for chronic fatigue syndrome, idiopathic chronic fatigue and fibromyalgia, which contains a processed product of Japanese horseradish (wasabi) as an acti...
|
|
WO/2018/118627A1 |
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
|
|
WO/2018/118662A1 |
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
|
|
WO/2018/112541A1 |
The present invention relates to methods of increasing vascular density and/or blood flow in tissue of a subject, and to increasing exercise capacity of a subject, the methods include administering to a subject an effective amount of an ...
|
|
WO/2018/118599A1 |
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
|
|
WO/2018/118957A1 |
This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof.
|
|
WO/2018/108991A2 |
The present invention is directed to a method of treating an amyloid-β peptide disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound that enhances mitoc...
|
|
WO/2018/103119A1 |
The present invention provides a hydrobromate of methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazole[1,2-a][1
,4]benzodiazepine-4-yl]propionate and related crystal forms and preparation method and use thereof. The hydrobromate has...
|
|
WO/2018/106339A1 |
Disclosed herein are compositions and methods for use in conjunction with surgical treatments related to tendon repair. Embodiments disclosed herein can locally reduce muscular activity and thereby reduce tension, for example after surgi...
|
|
WO/2018/105550A1 |
Provided is an amyotrophy inhibiting composition that comprises one or more kinds of peptides as active ingredient(s), said peptides being selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP and ...
|
|
WO/2018/105630A1 |
The present invention pertains to: a drug for preventing and/or treating cognitive dysfunction and/or a neurodegenerative disease accompanied by accumulation of prionoids, said drug comprising hemagglutinating virus of Japan envelope as ...
|
|
WO/2018/099946A1 |
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I), wherein one of T1 and T2 is OR1 or OR2; and the other of T1 and T2 i...
|
|
WO/2018/101398A1 |
The present invention provides a pharmaceutical composition for use in the treatment or prevention of inflammatory bowel disease (IBD). More particularly, the present invention provides a pharmaceutical composition that contains apelin o...
|
|
WO/2017/083776A9 |
The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.
|
|
WO/2018/096100A1 |
The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prio...
|
|
WO/2018/097733A2 |
A composition for the prevention and/or treatment of chronic fatigue syndrome (CFS)/ myalgia encephalomyelitis (ME) / systemic exertion intolerance disease (SEID) is described. Also described is a method for diagnosis of a patient with c...
|
|
WO/2018/091688A1 |
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...
|
|
WO/2018/090792A1 |
Disclosed are a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, a preparation and the use thereof in the preparation of a drug for treating diseases, disorders or conditions benefiting from the ...
|
|
WO/2018/091691A1 |
The present invention relates to LSD1 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a diseas...
|
|
WO/2018/091689A1 |
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...
|
|
WO/2018/088501A1 |
Provided is a method for inducing differentiation of pluripotent stem cells into somatic cells using a medium containing heparin binding growth factor, characterized by comprising contacting starting cells with a conjugate in which a lam...
|
|
WO/2018/083271A1 |
The present application is concerned with methods for increasing the bioavailability and/or activity of agents and in particular allows selective targeting of an agent to, or via, the liver or allows the liver to be bypassed. By selectin...
|
|
WO/2018/079719A1 |
The purpose of the invention is to provide a composition that has high biological safety and contributes to the activation of PGC-1α. Also, the purpose of the invention is to provide a use for said composition for activating PGC-1α and...
|
|
WO/2018/078134A1 |
The present invention relates to compositions and methods for the treatment of myotonic dystrophy.
|
|
WO/2018/077310A1 |
Disclosed is a vitamin C sodium-containing effervescent tablet, comprising the following components in parts by weight: 200-1120 parts of vitamin C sodium, 560-1300 parts of tartaric acid, 600-1500 parts of sodium bicarbonate, and 200-60...
|
|
WO/2018/079715A1 |
The purpose of the invention is to provide a composition that has high biological safety and contributes to the inhibition of FOXO1 activity. Also, the purpose of the invention is to provide a use for said composition for inhibiting FOXO...
|
|
WO/2018/076107A1 |
In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof minocycline, or a functional derivative thereof, and hydroxychloroquine, or a fun...
|
|
WO/2018/078131A1 |
The present invention relates to compositions and methods for the treatment of myotonic dystrophy.
|
|
WO/2018/076108A1 |
ABSTRACT In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neuro...
|
|
WO/2018/073414A1 |
The invention concerns the use of Lepista flaccida intended for treating a disease caused by a nonsense mutation of a gene resulting in the premature introduction of a UGA and/or UAA stop codon. It also concerns a Lepista flaccida extrac...
|
|
WO/2018/075858A1 |
This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, derm...
|
|
WO/2018/070510A1 |
Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass reduction, even for the elderly and even without requiring exercise, by inducing myogenesis. Provided is a composition for treating...
|
|
WO/2018/066427A1 |
The present invention addresses the problem of providing a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction and a composition for improving learning disorders. Provided is a composition that c...
|
|
WO/2018/066394A1 |
Provided is a composition that improves the flexibility of muscles by oral intake. The composition, which makes muscles flexible by oral intake, comprises an n-3 highly unsaturated fatty acid as an active ingredient. The n-3 highly unsat...
|
|
WO/2018/067879A1 |
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes ...
|
|
WO/2018/060418A1 |
The present invention relates to a substance selected from the group comprising irinotecan, an irinotecan active metabolite, 5-fluoro-uracile, a pharmaceutical salt thereof and a mixture thereof, for use in the treatment of fibrosis.
|
|
WO/2018/053653A1 |
The present matter relates to compositions comprising Teneurin C-terminal Associated Peptide – 1 (TCAP-1) and methods and uses of same for enhancing and/or restoring muscle function.
|
|
WO/2018/053632A1 |
Methods for modifying a dystrophin gene are disclosed, for restoring dystrophin expression within a cell having an endogenous frameshift or nonsense mutation within the dystrophin gene. The methods comprise introducing a first cut within...
|
|
WO/2018/056871A1 |
The invention relates to the field of molecular medicine. The subject matter of the invention is a use of oligonucleotide analogues, where one or more phosphodiester groups are substituted with a phosphoryl guanidine group, and derivativ...
|
|
WO/2018/052114A1 |
The present invention pertains to a pharmaceutical composition which contains a morphinan derivative exhibiting the action of an opioid δ receptor agonist. By administering the pharmaceutical composition provided by the present inventio...
|
|
WO/2018/051355A1 |
Methods of treating Duchenne muscular dystrophy (DMD), as well as methods of reducing the dose of steroids used to treat DMD are provided. Kits comprising tamoxifen and citrulline, arginine or a combination thereof, are also provided.
|
|
WO/2018/052082A1 |
This Lin28a activator includes, as an active ingredient, a polysaccharide which contains at least one substance selected from the group consisting of ribose, xylose, and derivatives of each. A monocyte dedifferentiation inducer includes,...
|
|
WO/2018/053004A2 |
Pharmaceutical compositions that stabilize a Clostridial toxin active ingredient are described. The compositions can be liquid or solid compositions, and comprise a surfactant and an antioxidant. In some embodiments, the compositions com...
|
